Abstract

BackgroundEvidence supporting corticosteroids adjunctive treatment (CAT) for Pneumocystis jirovecii pneumonia (PCP) in non-HIV patients is highly controversial. We aimed to systematically review the literature and perform a meta-analysis of available data relating to the effect of CAT on mortality of PCP in non-HIV patients.MethodsWe searched Pubmed, Medline, Embase, and Cochrane database from 1989 through 2019. Data on clinical outcomes from non-HIV PCP were extracted with a standardized instrument. Heterogeneity was assessed with the I2 index. Pooled odds ratios and 95% confidence interval were calculated using a fixed effects model. We analyzed the impact of CAT on mortality of non-HIV PCP in the whole PCP population, those who had hypoxemia (PaO2 < 70 mmHg) and who had respiratory failure (PaO2 < 60 mmHg).ResultsIn total, 259 articles were identified, and 2518 cases from 16 retrospective observational studies were included. In all non-HIV PCP cases included, there was an association between CAT and increased mortality (odds ratio, 1.37; 95% confidence interval 1.07–1.75; P = 0.01). CAT showed a probable benefit of decreasing mortality in hypoxemic non-HIV PCP patients (odds ratio, 0.69; 95% confidence interval 0.47–1.01; P = 0.05). Furthermore, in a subgroup analysis, CAT showed a significantly lower mortality in non-HIV PCP patients with respiratory failure compared to no CAT (odds ratio, 0.63; 95% confidence interval 0.41–0.95; P = 0.03).ConclusionsOur meta-analysis suggests that among non-HIV PCP patients with respiratory failure, CAT use may be associated with better clinical outcomes, and it may be associated with increased mortality in unselected non-HIV PCP population. Clinical trials are needed to compare CAT vs no-CAT in non-HIV PCP patients with respiratory failure. Furthermore, CAT use should be withheld in non-HIV PCP patients without hypoxemia.

Highlights

  • Pneumocystis jirovecii pneumonia (PCP) is a major cause of acute respiratory failure and death in immunocompromised patients

  • Literature search The literature search yield a total of 259 articles possibly related to non-HIV PCP with corticosteroids adjunctive treatment (CAT)

  • 66 articles with data on treatment of non-HIV PCP remained for full-text review

Read more

Summary

Introduction

Pneumocystis jirovecii pneumonia (PCP) is a major cause of acute respiratory failure and death in immunocompromised patients. The mortality associated with PCP in the non-HIV population group remains high, ranging from 19 to 76% [3,4,5], despite the availability of effective antimicrobial agents such as trimethoprim/sulfamethoxazole (TMP-SMZ) and pentamidine. Studies done in HIV-positive patients showed that corticosteroids adjunctive treatment (CAT) was associated with a dramatic decrease in mortality during PCP episodes [6, 7]. The pathophysiology of PCP may differ between patients with and without HIV infection These differences between the two populations might affect the ability of steroids therapy to provide therapeutic benefits [8]. Evidence supporting corticosteroids adjunctive treatment (CAT) for Pneumocystis jirovecii pneumonia (PCP) in non-HIV patients is highly controversial. We aimed to systematically review the literature and perform a metaanalysis of available data relating to the effect of CAT on mortality of PCP in non-HIV patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call